Financial Analysis: LadRx (OTCMKTS:CYTR) vs. CERo Therapeutics (NASDAQ:CERO)

CERo Therapeutics (NASDAQ:CERO) and LadRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a summary of recent ratings and target prices for CERo Therapeutics and LadRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	0	0	2	1	3.33
LadRx	0	0	0	0	0.00

CERo Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 1,220.75%. Given CERo Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than LadRx.

Profitability

This table compares CERo Therapeutics and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-108.43%
LadRx	N/A	-67.61%	-45.39%

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 0.1% of LadRx shares are held by institutional investors. 12.7% of CERo Therapeutics shares are held by company insiders. Comparatively, 12.8% of LadRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CERo Therapeutics and LadRx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$2.54 million	N/A	N/A
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

Risk and Volatility

CERo Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.

Summary

CERo Therapeutics beats LadRx on 7 of the 10 factors compared between the two stocks.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.